Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
07/29BRISTOL MYERS SQUIBB : Goldman Sachs Adjusts Price Target for Bristol-Myers Squi..
MT
07/29BRISTOL MYERS SQUIBB : Morgan Stanley Lifts Price Target on Bristol-Myers Squibb..
MT
04/30BRISTOL MYERS SQUIBB : Morgan Stanley Cuts Bristol-Myers Squibb to Equal-Weight ..
MT
04/13BRISTOL MYERS SQUIBB : Truist Securities Upgrades Bristol-Myers Squibb to Buy Fr..
MT
03/17BRISTOL MYERS SQUIBB : BofA Notes Bristol-Myers Squibb's $20 Billion Product Cyc..
MT
01/27BRISTOL MYERS SQUIBB : Berenberg Adjusts Price Target on Bristol-Myers Squibb to..
MT
01/15BRISTOL MYERS SQUIBB : UBS Adjusts Price Target on Bristol-Myers Squibb to $66 F..
MT
2020BRISTOL MYERS SQUIBB : Goldman Sachs Upgrades Bristol-Myers Squibb to Conviction..
MT
2020BRISTOL MYERS SQUIBB : Mizuho Adjusts Bristol-Myers Squibb's Price Target to $3...
MT
2020BRISTOL MYERS SQUIBB : Societe Generale Upgrades Bristol-Myers Squibb to Buy Fro..
MT
2020BRISTOL MYERS SQUIBB : Bernstein Reinstates Bristol-Myers Squibb at Market Perfo..
MT
2020BRISTOL MYERS SQUIBB : Gabelli Downgrades Bristol-Myers Squibb to Hold from Buy
MT
2020BRISTOL MYERS SQUIBB : Boosts 2020 Guidance
DJ
2019Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
RE
2019Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide
RE
2019Starboard gauges Bristol-Myers shareholder support for Celgene deal
RE
2018AstraZeneca cancer drug hits second goal by extending survival
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018Keytruda sales power Merck to quarterly beat
RE
2018Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
2017Roche drug cocktail doubles chance of holding lung cancer at bay
RE
2017Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
RE
2017Bristol-Myers shares fall on lung cancer timeline setback
RE
2017Deutsche Bank to pay $95 million to end U.S. tax fraud case
RE
2016Bristol lung-cancer setback puts rival Merck drug in driver seat
RE
2016BRISTOL MYERS SQUIBB : Merck sales disappoint as Januvia, Remicade fall short
RE
2016Merck gives cautious 2016 outlook as sales of top medicines lag
RE
2015Wall Street down for second day after rally; healthcare gains
RE
2014Pfizer dampens Astra bid hopes with German Merck cancer deal
RE
2014AstraZeneca cancer pipeline seen as draw for Pfizer
RE
2014Trade group seeks more U.S. pressure on India over patent protection
RE
2014AstraZeneca profits heading south as patent losses bite
RE
2014Ablynx agrees Merck cancer deal worth up to 1.7 billion euros
RE
2013AstraZeneca to buy Bristol out of diabetes venture for up to $4.1 billion
RE
2013AstraZeneca to buy Bristol out of diabetes venture for up to $4.1 billion
RE
2013GSK cancer vaccine disappoints in melanoma trial
RE
2013Fast-growing Humira extends domination of AbbVie
RE
2013Investors pin hopes on second-half earnings rebound
RE
2013Roche halts diabetes drug trial in blow to pipeline
RE
2013Bayer shares at record after upbeat drug sales view
RE
2013Pfizer, Lilly beat Street; generics take toll
RE
2013Pfizer fourth-quarter results top forecast, gives cautious 2013 view
RE
2012J&J hit by strong dollar, CEO eyes pruning units
RE
2012AMYLIN REJECTED $3.5 BILLION BRISTOL : Bloomberg
RE
Upcoming event on BRISTOL-MYERS SQUIBB COMPANY